Essential Blood Tests for Acute Coronary Syndrome Evaluation
Serial cardiac troponin (troponin I or T) measured at presentation and 3-6 hours after symptom onset is the cornerstone blood test for evaluating possible acute coronary syndrome, with additional testing beyond 6 hours if initial results are normal but clinical suspicion remains intermediate-to-high 1.
Primary Diagnostic Testing
Cardiac Troponin - The Gold Standard
High-sensitivity cardiac troponin (hs-cTn) should be measured immediately upon presentation with results available within 60 minutes 2. The testing strategy depends on your available assay:
- 0h/1h algorithm: Blood sampling at presentation and 1 hour later (preferred if validated hs-cTn available) 2
- 0h/2h algorithm: Alternative timing if 0h/1h not validated for your assay 2
- 0h/3h protocol: Acceptable when using contemporary (non-high-sensitivity) troponin assays 1
Critical timing consideration: If symptom onset timing is unclear, use the time of presentation as your reference point for serial measurements 1, 3.
Additional troponin at 3 hours is recommended if the first two measurements in the 0h/1h algorithm are inconclusive and clinical suspicion persists 2. For patients presenting within 6 hours of symptom onset with normal initial troponins but intermediate/high clinical suspicion, obtain additional levels beyond 6 hours 1.
What NOT to Order
CK-MB and myoglobin are NOT useful for ACS diagnosis when contemporary troponin assays are available (Class III recommendation) 1. These older biomarkers add no diagnostic value and should be abandoned in routine practice.
Supplementary Blood Tests
Hemoglobin/Complete Blood Count
Hemoglobin measurement is recommended to detect anemia, which can both mimic ACS symptoms and impact therapeutic decisions (particularly regarding bleeding risk with antiplatelet/anticoagulant therapy) 1, 4. Anemia may reveal occult GI bleeding that would contraindicate aggressive antithrombotic therapy.
Renal Function (Creatinine/eGFR)
Serum creatinine and estimated glomerular filtration rate (eGFR) should be measured 1. This is critical because:
- Chronic kidney disease causes persistently elevated troponin levels, complicating interpretation
- In patients with creatinine >220 μmol/L (>2.5 mg/dL) and chronically elevated troponin, serial troponin measurements at 0 and 12 hours help identify acute changes 5
- Renal function affects medication dosing and bleeding risk stratification
Glucose
Blood glucose measurement at presentation helps identify diabetes (a major ACS risk factor) and can be incorporated into laboratory risk scores that improve rule-out strategies 6.
Optional Prognostic Markers
B-type natriuretic peptide (BNP) or NT-proBNP may be reasonable for additional prognostic information (Class IIb recommendation) 1. These are NOT diagnostic for ACS but provide independent prognostic value for short- and long-term outcomes 7. Consider ordering when risk stratification beyond troponin is needed, particularly in patients with heart failure or hemodynamic instability.
Common Pitfalls to Avoid
Don't rely on a single troponin measurement: The diagnosis requires demonstrating a rising and/or falling pattern, not just an elevated value 1
Don't order troponin "just once" in early presenters: Patients presenting <3 hours from symptom onset frequently have false-negative initial troponins and require serial testing 1
Don't ignore chronically elevated troponins in renal failure patients: Look for dynamic changes (≥20% change if initially elevated, or ≥3 standard deviations if near the 99th percentile) rather than absolute values 1
Don't order multiple redundant cardiac biomarkers: Additional markers like h-FABP, copeptin, myeloperoxidase, or CK-MB alongside hs-cTn are NOT recommended for routine diagnostic purposes 2
Avoid point-of-care troponin for definitive diagnosis: POC troponin has substantially lower sensitivity than central laboratory methods and should only provide preliminary information 1
Risk Stratification Laboratory Panels
Beyond diagnosis, consider measuring red cell distribution width (RDW) as part of a comprehensive laboratory score for risk stratification, which when combined with glucose, eGFR, and hs-cTn can identify very low-risk patients suitable for early discharge 6. However, this approach requires local validation and is not yet standard practice.
The evidence strongly supports a focused approach: serial high-sensitivity troponin, hemoglobin, creatinine, and glucose form the essential laboratory panel, with BNP reserved for prognostic refinement in selected cases. This strategy maximizes diagnostic accuracy while avoiding unnecessary testing that doesn't improve patient outcomes.